CSL Limited (CSL.AX) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2026-06-30. CSL.AX files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.89% | 30.00% | Pass |
| Interest-bearing investments | 2.55% | 30.00% | Pass |
| Non-permissible income | 0.19% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.88% | 33.00% | Fail |
| Interest-bearing investments | 4.50% | 33.00% | Pass |
| Non-liquid assets | 87.32% | at least 20.00% | Pass |
| Non-permissible income | 0.19% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.88% | 33.33% | Fail |
| Cash + interest-bearing securities | 4.50% | 33.33% | Pass |
| Accounts receivable | 12.68% | 33.33% | Pass |
| Non-permissible income | 0.19% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.88% | 33.33% | Fail |
| Cash + interest-bearing securities | 4.50% | 33.33% | Pass |
| Accounts receivable | 12.68% | 50.00% | Pass |
| Non-permissible income | 0.19% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.24% | 33.00% | Pass |
| Cash + interest-bearing securities | 2.10% | 33.00% | Pass |
| Accounts receivable | 3.83% | 33.00% | Pass |
| Non-permissible income | 0.19% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 15.57% | 33.00% | Pass |
| Cash + interest-bearing securities | 1.90% | 49.00% | Pass |
| Accounts receivable | 3.45% | 49.00% | Pass |
| Non-permissible income | 0.19% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 15.57% | 33.33% | Pass |
| Cash + interest-bearing securities | 1.90% | 33.33% | Pass |
| Accounts receivable | 5.35% | 49.00% | Pass |
| Non-permissible income | 0.19% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 63.40 | NEUTRAL |
| Stochastic %K (14) | 14.10 | BUY |
| CCI (20) | 2.87 | NEUTRAL |
| Williams %R (14) | -85.90 | BUY |
| MACD (12,26,9) | -1.78 | SELL |
| ROC (10) | -1.75 | SELL |
| Momentum (10) | -2.98 | SELL |
| EMA (10) | 169.29 | SELL |
| SMA (10) | 170.77 | SELL |
| EMA (20) | 163.71 | BUY |
| SMA (20) | 167.29 | SELL |
| EMA (30) | 157.22 | BUY |
| SMA (30) | 155.40 | BUY |
| EMA (50) | 147.41 | BUY |
| SMA (50) | 141.39 | BUY |
| EMA (100) | 139.02 | BUY |
| SMA (100) | 124.45 | BUY |
| EMA (200) | 149.55 | BUY |
| SMA (200) | 140.63 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.